Amgen at these prices ought to be buying up Cytokinetics and thus be ready should things work out FDA wise to easily take them over. Certainly a reasonable approach if you're cold-hearted, ruthless bussinessman...
an interesting thought. if shareholders were offerred a certain buyout price and Amgen happened to be possessor of a large number of shares then a clearer road ahead for A could exist to buyout CYTK at a more favorable price to A. I don't think I"d like that very much because our potential profits are on the line.
Amgen has the best info on the heart drug trial. If it works and gets approved it will be a blockbuster.
A problem for Amgen making a takover offer now is that they would be acting on inside information and that's not legal. Any offer from them has to wait untill the trial results are unblinded and made public.